A Phase 2 interventional study of ibuprofen and ibuprofen in Pain, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-03-22.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.
Among the 86 studies testing ibuprofen in Pain, this one is the 26th largest by enrollment, is one of 4 that started in 2009, is one of 8 in phase 2, and was the 12th registered.
10,071 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi · Sites in Pakistan
Ages 18–60
October University for Modern Sciences and Arts · Sites in Egypt
Ages 6–12
Armed Forces Institute of Dentistry, Pakistan · Sites in Pakistan
Ages 18–50 · Healthy volunteers
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–80
Benaroya Research Institute · Sites in United States
Ages 18+ · Men only · Healthy volunteers
By country, each count listing its studies:
Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 16 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 22 · Phase 4 30
First in 1998; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 196 is above the median of 66 across 8,507 interventional studies indexed under Pain.
Median enrollment 100 across the 86 interventional studies. Of the 69 that completed or were terminated, 32 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 86 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
74 studies in Pain by Pfizer: none open now, none under way, none of them phase 3. Of 72 finished, 34 (47%) have results posted.
Among the 74 studies in Pain by Pfizer, this one is the 38th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2009, is one of 20 in phase 2, and was the 34th registered.
Pfizer’s Pain studies by the year they started, since 2001.
2 of the studies testing ibuprofen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07275710Armed Forces Post Graduate Medical Institute (AFPGMI), RawalpindiRole of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam. | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 86 studies testing ibuprofen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 74 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of a single dose of an ibuprofen 600 mg extended release formulation in post-operative dental pain. There is concern that the manufacturing process may affect the performance characteristics of the selected prototype. Therefore, two formulations of this prototype manufactured by two different processes, [roller compaction] and [wet granulation] will be included in this study. The preferred prototype manufactured by two different methods will be compared to placebo and each other. This study will also characterize the pharmacokinetic/pharmacodynamic relationship with these formulations.
Inclusion Criteria:
INCLUSION CRITERIA:
Exclusion Criteria:
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 x 600 mg ibuprofen IR/ER-roller compaction caplet
Drug: ibuprofen
1 x 600 mg ibuprofen IR/ER-Wet granulation caplet
Drug: ibuprofen
1x 220 mg naproxen sodium (Aleve caplet)
Drug: naproxen
1 x placebo caplet
Drug: Placebo
Time-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12)
Pain intensity difference (PID) score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -12 to 36 where higher positive values indicated improvement (decrease in pain intensity).
Time frame: Baseline (0 hour) to 12 hours post dose
Time-weighted Sum of Pain Intensity Difference Score From 8 to 12 Hours (SPID 8-12)
PID score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID score derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -4 to 12 where higher positive values indicated improvement (decrease in pain intensity).
Time frame: 8 to 12 hours post dose
Time to First Perceptible Pain Relief
Time to first perceptible relief (confirmed by meaningful relief) was defined as the elapsed time from dosing until the participant depresses the first stopwatch labelled "first perceptible relief", if the participant also depressed the second stopwatch labelled as "meaningful relief" by 6 hours. If the confirmation was not achieved, the participant was censored at 6 hours. Perceptible relief defined as when participant first begins to feel any pain relieving effect whatsoever of the drug. Does not necessarily mean the participant feels completely better, but when the participant first feels any difference in the pain he/she has currently.
Time frame: Baseline to 6 hours
Time to Treatment Failure
Time to first rescue medication or discontinuation due to lack of efficacy
Time frame: Baseline to 24 hours
Percentage of Participants With Treatment Failure
Treatment failure defined as use of rescue medication or discontinuation due to lack of efficacy.
Time frame: 8, 9, 10, 11, and 12 hours
Time-weighted Sum of Pain Intensity Difference From 0 to 4 Hours (SPID 0-4) and 4 to 8 Hours (SPID 4-8)
Time-weighted sum of PID score. PID based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID score derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -4 to 12 where higher positive values indicated improvement (decrease in pain intensity).
Time frame: 0 to 4 hours and 4 to 8 hours
Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores (SPRID)
Time-weighted sum of PRID score where PRID=PID+PR. PID: 4-point categorical pain intensity difference scale, 0 (none) to 3 (severe), score derived by subtracting postdose score from baseline, ranged from -1 to 3. Baseline pain intensity score of at least 2 required for enrollment. Higher positive PID values = improvement. PR: 5-point categorical pain relief scale None (0), A Little (1), Some (2), A Lot (3) or Complete (4). SPRID 0-4, SPRID 4-8, and SRID 8-12 scores ranged from -4 to 28, SPRID 0-12 ranged from -12 to 84, higher scores = greater improvement.
Time frame: 0 to 4 hours, 4 to 8 hours, 8 to 12 hours, and 0 to 12 hours
Time-weighted Sum of Pain Relief Scores (TOTPAR)
TOTPAR based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None (0), A Little (1), Some (2), A Lot (3) or Complete (4). Higher scores indicated improvement (better pain relief). For time-weighted sum of pain relief scores from 0 to 4 hours (TOTPAR 0-4), from 4 to 8 hours (TOTPAR 4-8), and from 8 to 12 hours (TOTPAR 8-12): range of scores 0 (worst) to 16 (best). TOTPAR 0-12 range of scores 0 (worst) to 48 (best).
Time frame: 0 to 4 hours, 4 to 8 hours, 8 to 12 hours, and 0 to 12 hours
Percentage of Participants Achieving First Perceptible Relief Confirmed by Meaningful Relief
The elapsed time from dosing until the participant indicated first perceptible relief, provided the participant also indicated achieving meaningful relief. Perceptible relief defined as when participant first begins to feel any pain-relieving effect whatsoever of the drug. Does not necessarily mean the participant feels completely better, but when the participant first feels any difference in the pain he/she currently has now.
Time frame: 15, 30, 45, 60, 90, and 120 minutes and every 60 minutes up to 360 minutes
Time to Meaningful Pain Relief
Participants evaluated the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief, defined as relief from the pain that is considered meaningful to the participant.
Time frame: Baseline to 6 hours
Percentage of Participants Achieving Meaningful Pain Relief
Participants evaluated the time to first perceptible pain relief by depressing a stopwatch at the moment they first began to experience perceptible relief and the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief defined as relief from the pain that is considered meaningful to the participant.
Time frame: 15, 30, 45, 60, 90, and 120 minutes and every 60 minutes up to 360 minutes
Participant Global Evaluation of Study Medication at 12 Hours
Participant rated global evaluation of study medication; results reported by evaluation categories and included very poor (0), poor (1), fair (2), good (3), very good (4), and excellent (5).
Time frame: 12 hours
Participant Global Evaluation of Study Medication at 24 Hours
Participant rated global evaluation of study medication; results reported by evaluation categories and included very poor (0), poor (1), fair (2), good (3), very good (4), and excellent (5).
Time frame: 24 hours
Pain Intensity Difference (PID) Score
PID based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). PID score derived by subtracting postdose score from baseline score and could range from -1 to 3. A baseline pain intensity score of at least 2 was required for study enrollment. Higher positive PID values indicated greater improvement (decrease in pain intensity).
Time frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours
Pain Relief (PR) Score
PR score based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None \[0\], A Little \[1\], Some \[2\], A Lot \[3\] or Complete \[4\]. Higher scores indicated improvement (better pain relief).
Time frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours
Pain Relief Combined With Pain Intensity Difference (PRID) Score
PRID=PID+PR, where PID: 4-point categorical pain intensity difference scale, 0 (none) to 3 (severe), score derived by subtracting postdose score from baseline and could range from -1 to 3. Baseline pain intensity score of at least 2 was required for study enrollment. Higher positive PID values indicated improvement. PR: 5-point categorical pain relief scale (None \[0\], A Little \[1\], Some \[2\], A Lot \[3\], Complete \[4\]). PRID score could range from -1 to 7 where higher scores indicated better pain relief and decrease in pain intensity.
Time frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours
Peak Pain Relief Score
Maximum PR score over the scheduled pain relief assessments. PR score based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None (0), A Little (1), Some (2), A Lot (3) or Complete (4). Higher scores indicated improvement (better pain relief).
Time frame: Baseline to 12 hours
| Milestone | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| Started | 29 | 53 | 56 | 58 |
| Completed | 29 | 53 | 56 | 58 |
| Not completed | 0 | 0 | 0 | 0 |
Pain intensity difference (PID) score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -12 to 36 where higher positive values indicated improvement (decrease in pain intensity).
| units on a scale | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| Time-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12) | 0.05 ± 9.22 | 16.87 ± 9.35 | 17.34 ± 10.54 | 12.66 ± 10.02 |
PID score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID score derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -4 to 12 where higher positive values indicated improvement (decrease in pain intensity).
| units on a scale | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| Time-weighted Sum of Pain Intensity Difference Score From 8 to 12 Hours (SPID 8-12) | -0.03 ± 4.05 | 6.57 ± 4.44 | 7.14 ± 5.24 | 5.14 ± 5.02 |
Time to first perceptible relief (confirmed by meaningful relief) was defined as the elapsed time from dosing until the participant depresses the first stopwatch labelled "first perceptible relief", if the participant also depressed the second stopwatch labelled as "meaningful relief" by 6 hours. If the confirmation was not achieved, the participant was censored at 6 hours. Perceptible relief defined as when participant first begins to feel any pain relieving effect whatsoever of the drug. Does not necessarily mean the participant feels completely better, but when the participant first feels any difference in the pain he/she has currently.
| minutes | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| Time to First Perceptible Pain Relief | NA (NA to NA) | 29.4 (23.3 to 35.3) | 29.4 (26.1 to 36.2) | 32.1 (29.5 to 58.0) |
Time to first rescue medication or discontinuation due to lack of efficacy
| hours | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| Time to Treatment Failure | 1.7 (1.7 to 2.2) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Treatment failure defined as use of rescue medication or discontinuation due to lack of efficacy.
| percentage of participants | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| 8 hours | 82.8 | 11.3 | 12.5 | 24.1 |
| 9 hours | 82.8 | 11.3 | 12.5 | 25.9 |
| 10 hours | 82.8 | 17.0 | 12.5 | 27.6 |
| 11 hours | 82.8 | 20.8 | 14.3 | 27.6 |
| 12 hours | 82.8 | 20.8 | 17.9 | 32.8 |
Time-weighted sum of PID score. PID based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID score derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -4 to 12 where higher positive values indicated improvement (decrease in pain intensity).
| units on a scale | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| SPID 0-4 | -0.12 ± 2.57 | 5.44 ± 3.21 | 5.22 ± 2.90 | 3.96 ± 2.87 |
| SPID 4-8 | 0.31 ± 4.57 | 8.15 ± 4.48 | 8.13 ± 4.76 | 5.95 ± 4.74 |
Time-weighted sum of PRID score where PRID=PID+PR. PID: 4-point categorical pain intensity difference scale, 0 (none) to 3 (severe), score derived by subtracting postdose score from baseline, ranged from -1 to 3. Baseline pain intensity score of at least 2 required for enrollment. Higher positive PID values = improvement. PR: 5-point categorical pain relief scale None (0), A Little (1), Some (2), A Lot (3) or Complete (4). SPRID 0-4, SPRID 4-8, and SRID 8-12 scores ranged from -4 to 28, SPRID 0-12 ranged from -12 to 84, higher scores = greater improvement.
| units on a scale | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| SPRID 0-4 | 1.78 ± 5.45 | 15.48 ± 6.60 | 15.12 ± 6.10 | 11.97 ± 6.51 |
| SPRID 4-8 | 3.69 ± 10.63 | 23.21 ± 8.85 | 23.14 ± 10.12 | 17.71 ± 10.69 |
| SPRID 8-12 | 3.00 ± 9.38 | 19.36 ± 9.94 | 20.73 ± 11.43 | 15.86 ± 11.56 |
| SPRID 0-12 | 7.09 ± 21.00 | 48.76 ± 18.99 | 50.01 ± 22.32 | 38.45 ± 22.61 |
TOTPAR based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None (0), A Little (1), Some (2), A Lot (3) or Complete (4). Higher scores indicated improvement (better pain relief). For time-weighted sum of pain relief scores from 0 to 4 hours (TOTPAR 0-4), from 4 to 8 hours (TOTPAR 4-8), and from 8 to 12 hours (TOTPAR 8-12): range of scores 0 (worst) to 16 (best). TOTPAR 0-12 range of scores 0 (worst) to 48 (best).
| units on a scale | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| TOTPAR 0-4 | 1.91 ± 3.25 | 10.04 ± 3.66 | 9.90 ± 3.51 | 8.01 ± 3.96 |
| TOTPAR 4-8 | 3.38 ± 6.43 | 15.06 ± 4.76 | 15.02 ± 5.79 | 11.76 ± 6.35 |
| TOTPAR 8-12 | 3.03 ± 5.75 | 12.79 ± 5.97 | 13.59 ± 6.61 | 10.72 ± 6.89 |
| TOTPAR 0-12 | 7.04 ± 12.74 | 31.89 ± 10.67 | 32.67 ± 12.74 | 25.79 ± 13.48 |
The elapsed time from dosing until the participant indicated first perceptible relief, provided the participant also indicated achieving meaningful relief. Perceptible relief defined as when participant first begins to feel any pain-relieving effect whatsoever of the drug. Does not necessarily mean the participant feels completely better, but when the participant first feels any difference in the pain he/she currently has now.
| percentage of participants | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| 15 minutes | 3.4 | 17.0 | 19.6 | 8.6 |
| 30 minutes | 3.4 | 52.8 | 55.4 | 39.7 |
| 45 minutes | 6.9 | 64.2 | 73.2 | 56.9 |
| 60 minutes | 13.8 | 81.1 | 83.9 | 65.5 |
| 90 minutes | 13.8 | 83.0 | 87.5 | 72.4 |
| 120 minutes | 13.8 | 83.0 | 91.1 | 72.4 |
| 180 minutes | 13.8 | 83.0 | 91.1 | 72.4 |
| 240 minutes | 13.8 | 83.0 | 91.1 | 72.4 |
| 300 minutes | 13.8 | 83.0 | 91.1 | 72.4 |
| 360 minutes | 13.8 | 83.0 | 91.1 | 72.4 |
Participants evaluated the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief, defined as relief from the pain that is considered meaningful to the participant.
| minutes | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| Time to Meaningful Pain Relief | NA (NA to NA) | 59.7 (52.3 to 88.3) | 76.7 (56.5 to 99.3) | 84.1 (63.8 to 174.2) |
Participants evaluated the time to first perceptible pain relief by depressing a stopwatch at the moment they first began to experience perceptible relief and the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief defined as relief from the pain that is considered meaningful to the participant.
| percentage of participants | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| 15 minutes | 0.0 | 1.9 | 0.0 | 1.7 |
| 30 minutes | 0.0 | 9.4 | 10.7 | 3.4 |
| 45 minutes | 3.4 | 28.3 | 28.6 | 13.8 |
| 60 minutes | 3.4 | 50.9 | 39.3 | 31.0 |
| 90 minutes | 3.4 | 64.2 | 57.1 | 50.0 |
| 120 minutes | 6.9 | 71.7 | 71.4 | 56.9 |
| 180 minutes | 10.3 | 79.2 | 82.1 | 63.8 |
| 240 minutes | 10.3 | 83.0 | 89.3 | 67.2 |
| 300 minutes | 10.3 | 83.0 | 91.1 | 69.0 |
| 360 minutes | 13.8 | 83.0 | 91.1 | 72.4 |
Participant rated global evaluation of study medication; results reported by evaluation categories and included very poor (0), poor (1), fair (2), good (3), very good (4), and excellent (5).
| participants | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| Very poor | 20 | 2 | 2 | 7 |
| Poor | 4 | 1 | 0 | 1 |
| Fair | 1 | 3 | 4 | 8 |
| Good | 2 | 11 | 9 | 18 |
| Very good | 2 | 20 | 28 | 15 |
| Excellent | 0 | 16 | 13 | 9 |
Participant rated global evaluation of study medication; results reported by evaluation categories and included very poor (0), poor (1), fair (2), good (3), very good (4), and excellent (5).
| participants | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| Very poor | 20 | 2 | 2 | 7 |
| Poor | 4 | 1 | 0 | 1 |
| Fair | 1 | 2 | 3 | 4 |
| Good | 3 | 14 | 10 | 17 |
| Very good | 1 | 17 | 23 | 19 |
| Excellent | 0 | 16 | 18 | 10 |
PID based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). PID score derived by subtracting postdose score from baseline score and could range from -1 to 3. A baseline pain intensity score of at least 2 was required for study enrollment. Higher positive PID values indicated greater improvement (decrease in pain intensity).
| units on a scale | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| 15 minutes | -0.14 ± 0.44 | 0.09 ± 0.45 | 0.09 ± 0.35 | 0.05 ± 0.22 |
| 30 minutes | -0.14 ± 0.52 | 0.40 ± 0.69 | 0.34 ± 0.64 | 0.29 ± 0.53 |
| 45 minutes | -0.10 ± 0.56 | 0.77 ± 0.89 | 0.70 ± 0.78 | 0.53 ± 0.60 |
| 60 minutes | -0.10 ± 0.62 | 0.94 ± 0.99 | 1.00 ± 0.81 | 0.81 ± 0.76 |
| 90 minutes | -0.07 ± 0.59 | 1.25 ± 1.02 | 1.29 ± 0.87 | 1.05 ± 0.80 |
| 2 hours | 0.00 ± 0.65 | 1.51 ± 0.97 | 1.48 ± 0.91 | 1.05 ± 0.83 |
| 3 hours | 0.00 ± 0.85 | 1.70 ± 0.97 | 1.64 ± 0.88 | 1.24 ± 0.94 |
| 4 hours | 0.03 ± 0.94 | 1.81 ± 0.92 | 1.66 ± 0.94 | 1.24 ± 0.98 |
| 5 hours | 0.07 ± 0.92 | 1.74 ± 0.94 | 1.68 ± 0.97 | 1.22 ± 1.04 |
| 6 hours | 0.07 ± 0.92 | 1.62 ± 0.99 | 1.66 ± 0.98 | 1.22 ± 1.04 |
| 7 hours | 0.07 ± 0.92 | 1.51 ± 0.97 | 1.64 ± 0.98 | 1.12 ± 1.01 |
| 8 hours | 0.07 ± 0.92 | 1.47 ± 0.91 | 1.48 ± 1.06 | 1.14 ± 1.00 |
| 9 hours | 0.00 ± 0.80 | 1.34 ± 0.94 | 1.41 ± 1.06 | 1.00 ± 1.03 |
| 10 hours | -0.03 ± 0.78 | 1.26 ± 0.96 | 1.45 ± 1.11 | 1.02 ± 1.05 |
| 11 hours | -0.03 ± 0.82 | 1.23 ± 0.97 | 1.43 ± 1.11 | 1.03 ± 1.11 |
| 12 hours | -0.03 ± 0.82 | 1.26 ± 0.96 | 1.38 ± 1.09 | 0.95 ± 1.08 |
| 13 hours | 0.00 ± 0.85 | 1.25 ± 1.02 | 1.23 ± 1.14 | 0.95 ± 1.03 |
| 14 hours | 0.03 ± 0.91 | 1.15 ± 1.10 | 1.18 ± 1.15 | 0.93 ± 1.06 |
| 16 hours | -0.03 ± 0.82 | 1.08 ± 1.05 | 1.02 ± 1.10 | 0.95 ± 1.07 |
| 24 hours | 0.07 ± 1.00 | 0.89 ± 1.01 | 0.91 ± 1.13 | 0.97 ± 1.08 |
PR score based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None \[0\], A Little \[1\], Some \[2\], A Lot \[3\] or Complete \[4\]. Higher scores indicated improvement (better pain relief).
| units on a scale | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| 15 minutes | 0.07 ± 0.26 | 0.36 ± 0.71 | 0.29 ± 0.56 | 0.28 ± 0.64 |
| 30 minutes | 0.21 ± 0.62 | 1.02 ± 0.99 | 0.82 ± 0.86 | 0.79 ± 0.91 |
| 45 minutes | 0.31 ± 0.66 | 1.72 ± 1.21 | 1.55 ± 1.17 | 1.21 ± 1.07 |
| 60 minutes | 0.41 ± 0.68 | 2.04 ± 1.27 | 1.98 ± 1.17 | 1.67 ± 1.19 |
| 90 minutes | 0.41 ± 0.73 | 2.40 ± 1.29 | 2.50 ± 1.16 | 2.09 ± 1.19 |
| 2 hours | 0.55 ± 0.91 | 2.66 ± 1.21 | 2.77 ± 1.14 | 2.24 ± 1.19 |
| 3 hours | 0.55 ± 1.15 | 3.06 ± 1.05 | 3.04 ± 1.09 | 2.43 ± 1.20 |
| 4 hours | 0.62 ± 1.27 | 3.17 ± 0.98 | 3.07 ± 1.13 | 2.43 ± 1.27 |
| 5 hours | 0.66 ± 1.29 | 3.13 ± 0.98 | 3.07 ± 1.19 | 2.36 ± 1.37 |
| 6 hours | 0.72 ± 1.36 | 2.98 ± 1.07 | 3.09 ± 1.16 | 2.40 ± 1.40 |
| 7 hours | 0.72 ± 1.36 | 2.94 ± 1.01 | 3.02 ± 1.20 | 2.29 ± 1.39 |
| 8 hours | 0.66 ± 1.26 | 2.83 ± 1.12 | 2.77 ± 1.33 | 2.28 ± 1.42 |
| 9 hours | 0.66 ± 1.23 | 2.55 ± 1.31 | 2.77 ± 1.32 | 2.16 ± 1.41 |
| 10 hours | 0.59 ± 1.15 | 2.51 ± 1.32 | 2.77 ± 1.36 | 2.14 ± 1.41 |
| 11 hours | 0.59 ± 1.21 | 2.47 ± 1.32 | 2.71 ± 1.37 | 2.17 ± 1.46 |
| 12 hours | 0.55 ± 1.18 | 2.43 ± 1.38 | 2.57 ± 1.45 | 1.98 ± 1.52 |
| 13 hours | 0.62 ± 1.27 | 2.43 ± 1.46 | 2.39 ± 1.53 | 2.03 ± 1.50 |
| 14 hours | 0.66 ± 1.34 | 2.28 ± 1.49 | 2.27 ± 1.60 | 2.03 ± 1.57 |
| 16 hours | 0.59 ± 1.27 | 2.15 ± 1.47 | 2.00 ± 1.64 | 1.98 ± 1.57 |
| 24 hours | 0.69 ± 1.42 | 1.92 ± 1.53 | 1.77 ± 1.71 | 2.00 ± 1.58 |
PRID=PID+PR, where PID: 4-point categorical pain intensity difference scale, 0 (none) to 3 (severe), score derived by subtracting postdose score from baseline and could range from -1 to 3. Baseline pain intensity score of at least 2 was required for study enrollment. Higher positive PID values indicated improvement. PR: 5-point categorical pain relief scale (None \[0\], A Little \[1\], Some \[2\], A Lot \[3\], Complete \[4\]). PRID score could range from -1 to 7 where higher scores indicated better pain relief and decrease in pain intensity.
| units on a scale | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| 15 minutes | -0.07 ± 0.59 | 0.45 ± 1.08 | 0.38 ± 0.84 | 0.33 ± 0.80 |
| 30 minutes | 0.07 ± 1.00 | 1.42 ± 1.60 | 1.16 ± 1.40 | 1.09 ± 1.37 |
| 45 minutes | 0.21 ± 1.08 | 2.49 ± 2.04 | 2.25 ± 1.90 | 1.74 ± 1.58 |
| 60 minutes | 0.31 ± 1.14 | 2.98 ± 2.18 | 2.98 ± 1.90 | 2.48 ± 1.86 |
| 90 minutes | 0.34 ± 1.20 | 3.64 ± 2.22 | 3.79 ± 1.92 | 3.14 ± 1.88 |
| 2 hours | 0.55 ± 1.45 | 4.17 ± 2.08 | 4.25 ± 1.97 | 3.29 ± 1.91 |
| 3 hours | 0.55 ± 1.92 | 4.75 ± 1.94 | 4.68 ± 1.87 | 3.67 ± 2.03 |
| 4 hours | 0.66 ± 2.13 | 4.98 ± 1.80 | 4.73 ± 1.97 | 3.67 ± 2.15 |
| 5 hours | 0.72 ± 2.14 | 4.87 ± 1.83 | 4.75 ± 2.08 | 3.59 ± 2.32 |
| 6 hours | 0.79 ± 2.21 | 4.60 ± 1.96 | 4.75 ± 2.06 | 3.62 ± 2.35 |
| 7 hours | 0.79 ± 2.21 | 4.45 ± 1.90 | 4.66 ± 2.08 | 3.41 ± 2.32 |
| 8 hours | 0.72 ± 2.10 | 4.30 ± 1.95 | 4.25 ± 2.30 | 3.41 ± 2.35 |
| 9 hours | 0.66 ± 1.95 | 3.89 ± 2.14 | 4.18 ± 2.29 | 3.16 ± 2.36 |
| 10 hours | 0.55 ± 1.82 | 3.77 ± 2.19 | 4.21 ± 2.38 | 3.16 ± 2.38 |
| 11 hours | 0.55 ± 1.94 | 3.70 ± 2.22 | 4.14 ± 2.39 | 3.21 ± 2.50 |
| 12 hours | 0.52 ± 1.92 | 3.70 ± 2.24 | 3.95 ± 2.45 | 2.93 ± 2.53 |
| 13 hours | 0.62 ± 2.03 | 3.68 ± 2.39 | 3.63 ± 2.59 | 2.98 ± 2.46 |
| 14 hours | 0.69 ± 2.17 | 3.43 ± 2.51 | 3.45 ± 2.68 | 2.97 ± 2.54 |
| 16 hours | 0.55 ± 2.01 | 3.23 ± 2.43 | 3.02 ± 2.67 | 2.93 ± 2.57 |
| 24 hours | 0.76 ± 2.34 | 2.81 ± 2.45 | 2.68 ± 2.78 | 2.97 ± 2.58 |
Maximum PR score over the scheduled pain relief assessments. PR score based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None (0), A Little (1), Some (2), A Lot (3) or Complete (4). Higher scores indicated improvement (better pain relief).
| units on a scale | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| Peak Pain Relief Score | 1.00 ± 1.41 | 3.42 ± 0.82 | 3.39 ± 0.85 | 3.05 ± 1.16 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/29 (0%) | 8/29 (27.6%) |
| Ibuprofen IR/ER (Roller Compaction) | — | 0/53 (0%) | 3/53 (5.7%) |
| Ibuprofen IR/ER (Wet Granulation) | — | 0/56 (0%) | 8/56 (14.3%) |
| Naproxen | — | 0/58 (0%) | 6/58 (10.3%) |
| Event | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 6/29 | 1/53 | 5/56 | 2/58 |
| VomitingGastrointestinal disorders | 5/29 | 0/53 | 3/56 | 1/58 |
| HeadacheNervous system disorders | 1/29 | 2/53 | 1/56 | 1/58 |
| DizzinessNervous system disorders | 1/29 | 0/53 | 2/56 | 2/58 |
| MalaiseGeneral disorders | 0/29 | 1/53 | 0/56 | 0/58 |
| EpistaxiaRespiratory, thoracic and mediastinal disorders | 0/29 | 1/53 | 0/56 | 0/58 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 0/29 | 1/53 | 0/56 | 0/58 |
| PyrexiaGeneral disorders | 0/29 | 0/53 | 1/56 | 0/58 |
| ParaesthesiaNervous system disorders | 0/29 | 0/53 | 1/56 | 0/58 |
| PruritusSkin and subcutaneous tissue disorders | 0/29 | 0/53 | 1/56 | 0/58 |
| Age, Continuous(years) | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen | Total |
|---|---|---|---|---|---|
| Mean | 18.1 ± 2.1 | 18.6 ± 2.4 | 18.7 ± 2.7 | 18.3 ± 2.6 | 18.5 ± 2.5 |
| Sex: Female, Male(Participants) | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen | Total |
|---|---|---|---|---|---|
| Female | 12 | 22 | 23 | 24 | 81 |
| Male | 17 | 31 | 33 | 34 | 115 |
| Pain severity(participants) | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen | Total |
|---|---|---|---|---|---|
| Moderate | 18 | 29 | 33 | 34 | 114 |
| Severe | 11 | 24 | 23 | 24 | 82 |
| Pain intensity(mm) | Placebo | Ibuprofen IR/ER (Roller Compaction) | Ibuprofen IR/ER (Wet Granulation) | Naproxen | Total |
|---|---|---|---|---|---|
| Mean | 73.90 ± 11.60 | 77.06 ± 13.23 | 74.80 ± 12.40 | 75.12 ± 12.30 | 75.37 ± 12.44 |
Ran from May 2009 to primary completion in Aug 2009, 2 months.
Results were first posted in Mar 2018, 8 years 7 months after primary completion. A results delay was requested in Nov 2012.
Of 62 industry-sponsored phase 2 interventional studies under Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 2 months is below that.
Counting every sponsor, half of 186 studies reached it within 21 months; a quarter within 7 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen